PRFN.SW Kinarus Therapeutics (SIX) 29 Jan 2026: CHF 0.036 intraday on heavy volume, watch resistance
PRFN.SW stock trades intraday at CHF 0.036 on 29 Jan 2026 after a one-day drop of -8.12% and a surge in volume to 2,937,350 shares. Kinarus Therapeutics Holding AG (PRFN.SW) is listed on the SIX in Switzerland and shows wide intraday range, low liquidity but elevated activity relative to its 50-day average volume. The stock sits well below its 50-day average price of CHF 0.073 and 200-day average of CHF 0.074, raising near-term technical resistance while fundamental metrics point to continued development-stage risk.
PRFN.SW stock: intraday price action and volume
PRFN.SW stock opened at CHF 0.040, hit a day high of CHF 0.040 and a day low of CHF 0.0352, with the last print at CHF 0.036. The intraday volume of 2,937,350 is 3.42x the average volume of 859,130, placing PRFN.SW among the most active small-caps on SIX this session. Heavy trading with wide spreads is consistent with microcap listings and may amplify short-term moves.
PRFN.SW stock: fundamentals and ratios
Kinarus Therapeutics Holding AG reports an EPS of -0.001 and a negative PE reported as -36.20, reflecting loss-making status typical of clinical-stage biotech. Key balance metrics show a current ratio of 1.27 and cash per share of 0.000736, while enterprise value stands at CHF 305,000. These figures underline limited liquidity on the balance sheet and reliance on financing or partnerships for pipeline progress.
PRFN.SW stock: technical setup and resistance
Technically, PRFN.SW stock trades below the 50-day and 200-day averages (CHF 0.073 and CHF 0.074 respectively), signalling a medium-term downtrend. Immediate resistance sits near the prior open and intraday highs at CHF 0.040 and the 50-day average around CHF 0.073. Support is visible at the year low of CHF 0.034; a break below that could increase downside risk.
PRFN.SW stock: sector context and operational profile
Kinarus is described as a clinical-stage biopharmaceutical group focused on respiratory and ophthalmic therapies, though its exchange profile lists the sector as Industrials on SIX. Healthcare sector performance YTD is positive at 4.92%, suggesting stronger investor appetite in larger biotech peers. PRFN.SW’s small scale, with around 15 employees, distinguishes its risk and return profile from sector leaders like Roche and Novartis.
PRFN.SW stock: risks, catalysts and analyst view
Primary risks are clinical trial outcomes, funding needs and low free float liquidity. Catalysts include pipeline updates, partnerships or financing announcements. Analyst coverage is limited; consensus price targets are not available, so market moves react sharply to any news. Given microcap volatility, traders should expect frequent price swings and wide bid-ask spreads.
PRFN.SW stock: Meyka AI grade and model outlook
Meyka AI rates PRFN.SW with a score out of 100: 59.75 | Grade: C+ | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a target of CHF 0.065, implying an upside of 80.56% versus the current price CHF 0.036. Forecasts are model-based projections and not guarantees.
Final Thoughts
PRFN.SW stock is trading as one of the most active small-caps on the SIX intraday session, with CHF 0.036 last and volume at 2,937,350 shares. The price sits well below moving averages (50-day CHF 0.073, 200-day CHF 0.074), flagging technical resistance near CHF 0.040 and the 50-day average. Fundamentally, EPS of -0.001 and negative PE underline development-phase risks and funding sensitivity. Meyka AI’s model projects a CHF 0.065 target, representing implied upside of 80.56%, but that scenario depends on clinical or corporate catalysts. For traders, the intraday activity offers short-term liquidity and momentum plays. For investors, low cash per share and thin fundamentals argue for cautious position sizing. Use stop-loss discipline and watch corporate updates; our AI-powered market analysis platform flags PRFN.SW for close monitoring rather than immediate buy conviction. Forecasts are model-based projections and not guarantees.
FAQs
What is the current PRFN.SW stock price and intraday change?
PRFN.SW stock last traded at CHF 0.036, down -8.12% for the session. The intraday range was CHF 0.0352 to CHF 0.040 with volume of 2,937,350 shares.
What rating does Meyka AI give PRFN.SW stock?
Meyka AI rates PRFN.SW with a score of 59.75 out of 100, grade C+, and a HOLD suggestion. The grade combines benchmark, sector, metrics and analyst signals; it is informational only.
What is the Meyka AI forecast for PRFN.SW stock?
Meyka AI’s forecast model projects CHF 0.065 for PRFN.SW, an implied upside of 80.56% versus CHF 0.036. Forecasts are model-based projections and not guarantees.
What are the main risks for PRFN.SW stock?
Key risks include trial or development setbacks, funding dilution, low liquidity and wide spreads. Microcap status can cause amplified moves on sparse news or block trades.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
